SVB Securities analyst Marc Goodman initiated coverage of Biohaven (BHVN) with an Outperform rating and $24 price target. The firm likes the fast-follower strategy with the lead asset BHV-7000, which is relatively de-risked as a Kv7 channel activator, and notes Taldefgrobepalpha has a respectable chance of working in spinal muscular atrophy as an adjunctive therapy to standard of care and is currently being assessed in a Phase 3 pivotal trial. Further, Troriluzole remains a wild card with its Phase 3 programs in both obsessive compulsive disorder as well as spinal cerebellar ataxia, while the company’s leadership team has created a great deal of value with the monetization of the migraine franchise to Pfizer (PFE), SVB Securities argues.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BHVN:
- Piper ‘incrementally positive’ on Biohaven shares after BHV-7000 data
- J.P. Morgan Says These 2 Stocks Are Ready to Rip Higher — This Is What Makes Them Attractive Buys
- Biohaven rises 9.0%
- Biohaven initiated with an Overweight at JPMorgan
- Biohaven treatment of spinal muscular atrophy granted orphan designation
